Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Alterity Therapeutics LimitedNASDAQ: ATHE

Investing Cash Flow · Q2 FY2026 · quarter ended Dec 2025

Investing cash flow outflow grows to A$7.36M

Q2 FY2026 investing cash flow was A$7.36M, compared with A$0 a year earlier. Over 3 fiscal years it compounded at +338.2% a year.

Context

  • Investing cash flow amounted to 137.9% of revenue in FY2025, up 137.8 pp from a year earlier.
  • Investing cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$7.36M— QoQ
Last fiscal yearJun 2025
-A$7.5M+130973.1% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+130973.1%——
3-year CAGR+338.2%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

AUD · from the cash flow

Latest · FY2025
(7.5M) AUD
Year-over-year change
-130973.1%

Investing Cash Flow vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +130973.1% is the highest of 2, against a peer median of +217.2%.
  • Investing cash flow amounts to 137.9% of revenue for ATHE, versus a peer median of 29.1%.
ATHE Competitors
Investing Cash Flow for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATHEAlterity Therapeutics LimitedFY2025A$7.5M AUD+130973.1%+338.2%137.9%
DYAIDyadic International, Inc.LTM Mar 2026$866.18K USD+217.2%—29.1%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ATHE) —+217.2%—29.1%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Depreciation & Amortization75.37K54.21K102.26K147.53K139.72K
Deferred Income Tax2.33M(1.06M)2.99M00
Stock-Based Compensation1.88M1.51M966.57K881.95K979.92K
Change in Working Capital(4.22M)(447.68K)(3.94M)5.75M(613.68K)
Accounts Receivables(4.22M)(447.68K)(3.94M)4.62M104.07K
Inventory191.13K(2.21M)2.45M00
Accounts Payables432.91K2.6M(1.56M)1.1M0
Other Working Capital(624.03K)(393.29K)(889.52K)23.05K(717.75K)
Other Non-Cash Items(2.1M)455.57K(6.35M)(261.15K)190.62K
Operating Cash Flow(17.33M)(12.34M)(20.04M)(12.61M)(11.45M)
Capital Expenditures(10.47K)(89.15K)(7.31K)(5.72K)3
Acquisitions (Net)00000
Purchases of Investments0000(7.5M)
Sales of Investments00000
Other Investing Activities00(29.15K)00
Investing Cash Flow(10.47K)(89.15K)(36.46K)(5.72K)(7.5M)
Debt Repayment(58.29K)(34.51K)(59.92K)(10.37K)(127.1K)
Common Stock Issued39.24M17.18M316.68K10.14M42.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.49M)(836.97K)(132.41K)(918.02K)(2.77M)
Financing Cash Flow36.69M16.3M124.34K9.22M39.67M
Effect of Forex Changes(426.78K)2.81M914.94K260.36K(198.38K)
Net Change in Cash18.92M6.69M(19.03M)(3.13M)20.52M
Free Cash Flow(17.34M)(12.43M)(20.04M)(12.61M)(11.45M)

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.